Home 禄 Business 禄 Manufacturing
Qiagen optimistic
By Cathy Ding |
July 30, 2010, Friday
|
Print Edition
Print Edition
GERMAN biotechnology firm Qiagen hopes its revenue in China will nearly double this year with increasing demand for molecular testing.
The company, which provides sample and assay technologies for research institutions and pharmaceutical firms, has seen revenue increase more than 90 percent in China in the past year while that of the Asian Pacific region jumped about 40 percent.
Asia Pacific now contributes 15 percent of its global revenue, according to Victor Shi, president of Qiagen Asia Pacific.
The company has production bases in Shenzhen and Beijing.
The company, which provides sample and assay technologies for research institutions and pharmaceutical firms, has seen revenue increase more than 90 percent in China in the past year while that of the Asian Pacific region jumped about 40 percent.
Asia Pacific now contributes 15 percent of its global revenue, according to Victor Shi, president of Qiagen Asia Pacific.
The company has production bases in Shenzhen and Beijing.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
